keyword
MENU ▼
Read by QxMD icon Read
search

Kpc-3

keyword
https://www.readbyqxmd.com/read/29744043/genome-based-analysis-of-carbapenemase-producing-klebsiella-pneumoniae-isolates-from-german-hospital-patients-2008-2014
#1
Laura Becker, Martin Kaase, Yvonne Pfeifer, Stephan Fuchs, Annicka Reuss, Anja von Laer, Muna Abu Sin, Miriam Korte-Berwanger, Sören Gatermann, Guido Werner
Background: By using whole genome sequence data we aimed at describing a population snapshot of carbapenemase-producing K. pneumoniae isolated from hospitalized patients in Germany between 2008 and 2014. Methods: We selected a representative subset of 107 carbapenemase-producing K. pneumoniae clinical isolates possessing the four most prevalent carbapenemase types in Germany (KPC-2, KPC-3, OXA-48, NDM-1). Isolates were processed via illumina NGS. Data were analysed using different SNP-based mapping and de-novo assembly approaches...
2018: Antimicrobial Resistance and Infection Control
https://www.readbyqxmd.com/read/29621600/nosocomial-transmission-of-carbapenem-resistant-klebsiella-pneumoniae-in-an-italian-university-hospital-a-molecular-epidemiological-study
#2
Giovanni Sotgiu, Bianca Maria Are, Lucia Pesapane, Alessandra Palmieri, Narcisa Muresu, Andrea Cossu, Marco Dettori, Antonio Azara, Ida Iolanda Mura, Clementina Cocuzza, Stefano Aliberti, Andrea Piana
AIM: To describe the phenotypic and genotypic profiles of Klebsiella pneumonia carbapenemase-producing K. pneumonia (KPC-Kp) strains isolated from patients with invasive infections at an Italian university hospital in order to assess the epidemiological trend. METHODS: An observational prospective study was carried out at the University Hospital of Sassari, Italy, to detect KPC-Kp strains in patients with invasive bacteraemia. Isolates were identified phenotypically; carbapenemase production was assessed using phenotypic and genotypic methods...
April 2, 2018: Journal of Hospital Infection
https://www.readbyqxmd.com/read/29571838/multidrug-resistant-infections-in-long-term-care-facilities-extended-spectrum-%C3%AE-lactamase-producing-enterobacteriaceae-and-hypervirulent-antibiotic-resistant-clostridium-difficile
#3
Maria Giufrè, Marisa Accogli, Enrico Ricchizzi, Fabrizio Barbanti, Claudio Farina, Paolo Fazii, Romano Mattei, Mario Sarti, Agostino Barozzi, Rossella Buttazzi, Marina Cosentino, Maria Nardone, Vincenzo Savini, Patrizia Spigaglia, Maria Luisa Moro, Marina Cerquetti
Infections due to multidrug-resistant (MDR) organisms in long-term care facilities (LTCFs) residents constitute a public health concern. This multicenter study investigated the frequency of ESBL-producing pathogens and MDR Clostridium difficile in clinical specimens from LTCF residents in Italy. During October 2014-March 2015, all urine and diarrheic fecal samples from LTCF residents (≥65 years) with suspected urinary tract infection or C. difficile infection, respectively, received for diagnosis by 4 hospital laboratories located in different cities were analyzed...
February 26, 2018: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/29510189/in-vitro-activity-of-meropenem-vaborbactam-and-characterization-of-carbapenem-resistance-mechanisms-among-carbapenem-resistant-enterobacteriaceae-from-the-2015-meropenem-vaborbactam-surveillance-program
#4
Michael A Pfaller, Michael D Huband, Rodrigo E Mendes, Robert K Flamm, Mariana Castanheira
We evaluated meropenem-vaborbactam activity against 11,559 Enterobacteriaceae isolates, including 330 carbapenem-resistant phenotypes (CRE) and carbapenemase genotypes collected worldwide during 2015. Meropenem-vaborbactam (inhibitor at 8 mg/L) and comparators were susceptibility tested using reference broth microdilution methods. CRE isolates were screened for the presence of genes encoding carbapenemases and 292 (88.5%) of the CRE isolates carried these resistance genes. A total of 209 (63.3% of the CRE; 1...
March 3, 2018: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/29507064/pneumonia-and-renal-replacement-therapy-are-risk-factors-for-ceftazidime-avibactam-treatment-failures-and-resistance-among-patients-with-carbapenem-resistant-enterobacteriaceae-infections
#5
Ryan K Shields, M Hong Nguyen, Liang Chen, Ellen G Press, Barry N Kreiswirth, Cornelius J Clancy
Ceftazidime-avibactam was used to treat 77 patients with carbapenem-resistant Enterobacteriaceae (CRE) infections at our center. Thirty- and 90-day survival rates were 81% and 69%, respectively; these rates were higher than those predicted by SAPS II and SOFA scores at the onset of infection. Clinical success was achieved for 55% of patients but differed by the site of infection. Success rates were lowest for pneumonia (36%) and higher for bacteremia (75%) and urinary tract infections (88%). By multivariate analysis, pneumonia ( P = 0...
May 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29176971/occurrence-of-extended-spectrum-%C3%AE-lactamases-kpc-type-and-mcr-1-2-producing-enterobacteriaceae-from-wells-river-water-and-wastewater-treatment-plants-in-oltrep%C3%A3-pavese-area-northern-italy
#6
Mariasofia Caltagirone, Elisabetta Nucleo, Melissa Spalla, Francesca Zara, Federica Novazzi, Vittoria M Marchetti, Aurora Piazza, Ibrahim Bitar, Marica De Cicco, Stefania Paolucci, Giorgio Pilla, Roberta Migliavacca, Laura Pagani
To evaluate the water compartment antibiotic-resistance contamination rates, 11 wells, five streams, and four treatment plants located in the Oltrepò Pavese area were screened for the presence of third generation cephalosporins resistant Gram-negative bacteria. Enterobacteriaceae were also characterized for the Extended-Spectrum-β-Lactamases (ESBLs), carbapenemases, and mcr-1 genes presence. From December 2014 to November 2015, 246 water samples were filtered, plated on Plate Count Agar, MacConkey Agar, and MacConkey Agar with cefotaxime...
2017: Frontiers in Microbiology
https://www.readbyqxmd.com/read/28968012/-antimicrobial-susceptibility-profile-in-urinary-pathogens-causing-community-acquired-infections-in-diabetic-patients-in-colombia
#7
Laura Cristina Nocua-Báez, Jorge Alberto Cortés, Aura Lucía Leal, Gerson Fitzgerald Arias, María Victoria Ovalle-Guerro, Sandra Yamile Saavedra-Rojas, Giancarlo Buitrago, Javier Antonio Escobar-Pérez, Betsy Castro-Cardozo
INTRODUCTION: Urinary tract infection is the most common pathology in diabetic patients, and an important determinant of morbidity and mortality among them. The increasing resistance of uropathogens acquired in the community to commonly used antibiotics is alarming. OBJECTIVE: To identify the profile of antibiotic susceptibility of uropathogens responsible for communityacquired infections among diabetic patients in hospitals in Colombia. MATERIALS AND METHODS: We conducted a descriptive study in a subgroup of diabetic patients in the framework of a larger study in adults with urinary tract infection acquired in the community...
September 1, 2017: Biomédica: Revista del Instituto Nacional de Salud
https://www.readbyqxmd.com/read/28947474/pharmacokinetics-pharmacodynamics-of-cb-618-in-combination-with-cefepime-ceftazidime-ceftolozane-or-meropenem-the-pharmacological-basis-for-a-stand-alone-%C3%AE-lactamase-inhibitor
#8
Paul G Ambrose, Brian D VanScoy, Michael Trang, Jennifer McCauley-Miller, Haley Conde, Sujata M Bhavnani, Dylan C Alexander, Lawrence V Friedrich
A major challenge in treating patients is the selection of the "right" antibiotic regimen. Given that the optimal β-lactam/β-lactamase inhibitor pair is dependent upon the spectrum of β-lactamase enzymes produced and the frequency of resistance to the β-lactamase inhibitor, it might be useful if a stand-alone were available for the clinician to pair with the "right" β-lactam rather than only in a fixed combination. We describe herein a one-compartment in vitro infection model studies conducted to identify the magnitudes of the pharmacokinetic-pharmacodynamic (PK-PD) index for a β-lactamase inhibitor, CB-618, that would restore the activity of four β-lactam partner agents (cefepime, ceftazidime, ceftolozane, and meropenem) with various doses (1 or 2 g) and dosing intervals (8 or 12 h)...
December 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28844719/evaluation-of-a-rapid-immunochromatographic-test-for-detection-of-distinct-variants-of-klebsiella-pneumoniae-carbapenemase-kpc-in-enterobacteriaceae
#9
Ana C Ramos, Ana C Gales, Jussimara Monteiro, Suzane Silbert, Thomás Chagas-Neto, Antonia M O Machado, Cecilia G Carvalhaes
The rapid detection of KPC-producing Enterobacteriaceae by microbiology laboratories has been required for infectious control programs. Herein we evaluated the performance of a novel immunochromatographic test for detecting KPC-2-, KPC-3-, KPC-4-, KPC-6-, KPC-7-, KPC-8-, and KPC-11-producing isolates and the influence of different growth media on the test performance.
November 2017: Journal of Microbiological Methods
https://www.readbyqxmd.com/read/28739787/resistance-to-ceftazidime-avibactam-is-due-to-transposition-of-kpc-in-a-porin-deficient-strain-of-klebsiella-pneumoniae-with-increased-efflux-activity
#10
Kirk Nelson, Peera Hemarajata, Dongxu Sun, Debora Rubio-Aparicio, Ruslan Tsivkovski, Shangxin Yang, Robert Sebra, Andrew Kasarskis, Hoan Nguyen, Blake M Hanson, Shana Leopold, George Weinstock, Olga Lomovskaya, Romney M Humphries
Ceftazidime-avibactam is an antibiotic with activity against serine beta-lactamases, including Klebsiella pneumoniae carbapenemase (KPC). Recently, reports have emerged of KPC-producing isolates resistant to this antibiotic, including a report of a wild-type KPC-3 producing sequence type 258 Klebsiella pneumoniae that was resistant to ceftazidime-avibactam. We describe a detailed analysis of this isolate, in the context of two other closely related KPC-3 producing isolates, recovered from the same patient. Both isolates encoded a nonfunctional OmpK35, whereas we demonstrate that a novel T333N mutation in OmpK36, present in the ceftazidime-avibactam resistant isolate, reduced the activity of this porin and impacted ceftazidime-avibactam susceptibility...
October 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28630202/identifying-spectra-of-activity-and-therapeutic-niches-for-ceftazidime-avibactam-and-imipenem-relebactam-against-carbapenem-resistant-enterobacteriaceae
#11
Ghady Haidar, Cornelius J Clancy, Liang Chen, Palash Samanta, Ryan K Shields, Barry N Kreiswirth, M Hong Nguyen
We determined imipenem, imipenem-relebactam, ceftazidime, and ceftazidime-avibactam MICs against 100 CRE isolates that underwent whole-genome sequencing. Klebsiella pneumoniae carbapenemases (KPCs) were the most common carbapenemases. Forty-six isolates carried extended-spectrum β-lactamases (ESBLs). With the addition of relebactam, imipenem susceptibility increased from 8% to 88%. With the addition of avibactam, ceftazidime susceptibility increased from 0% to 85%. Neither imipenem-relebactam nor ceftazidime-avibactam was active against metallo-β-lactamase (MBL) producers...
September 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28590820/activity-of-ceftazidime-avibactam-against-clinical-isolates-of-klebsiella-pneumoniae-including-kpc-carrying-isolates-endemic-to-new-york-city
#12
Nyla Manning, Gregory Balabanian, Michael Rose, David Landman, John Quale
In this report, we examined the (1) activity of ceftazidime-avibactam against clinical isolates Klebsiella pneumoniae, including those harboring blaKPC , (2) potential mechanisms leading to reduced susceptibility, and (3) activity of ceftazidime-avibactam when combined with other agents. Of 802 carbapenem-resistant isolates of K. pneumoniae gathered from New York City from 1999 to 2014, all were susceptible to ceftazidime-avibactam. Minimum inhibitory concentrations (MICs) were higher in isolates with K. pneumoniae, with the carbapenemase (KPC)-3 (compared to KPC-2), and those with a frameshift mutation in ompK35...
January 2018: Microbial Drug Resistance: MDR: Mechanisms, Epidemiology, and Disease
https://www.readbyqxmd.com/read/28559268/circulation-of-bla-kpc-3-carrying-incx3-plasmids-among-citrobacter-freundii-isolates-in-an-italian-hospital
#13
Carolina Venditti, Daniela Fortini, Laura Villa, Antonella Vulcano, Silvia D'Arezzo, Alessandro Capone, Nicola Petrosillo, Carla Nisii, Alessandra Carattoli, Antonino Di Caro
Colonizations due to carbapenem-resistant Enterobacteriaceae (CRE) are a source of antimicrobial resistance transmission in health care settings. Eleven Citrobacter freundii strains producing KPC-3 carbapenemase were isolated from rectal swabs during a 3-year surveillance program. bla KPC-3 -carrying plasmids were found to belong to the IncX3 group in 9 of the 11 strains, and complete nucleotide sequences were obtained for 2 of them. Our results highlight the possible role of C. freundii as reservoir of resistance genes...
August 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28472479/kpc-3-producing-st167-escherichia-coli-from-mussels-bought-at-a-retail-market-in-tunisia
#14
Yosra Mani, Wejdene Mansour, Hedi Mammeri, Erick Denamur, Estelle Saras, Noureddine Boujâafar, Olfa Bouallègue, Jean-Yves Madec, Marisa Haenni
No abstract text is available yet for this article.
August 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28470337/synergistic-activity-of-synthetic-n-terminal-peptide-of-human-lactoferrin-in-combination-with-various-antibiotics-against-carbapenem-resistant-klebsiella-pneumoniae-strains
#15
P Morici, W Florio, C Rizzato, E Ghelardi, A Tavanti, G M Rossolini, A Lupetti
The spread of multi-drug resistant (MDR) Klebsiella pneumoniae strains producing carbapenemases points to a pressing need for new antibacterial agents. To this end, the in-vitro antibacterial activity of a synthetic N-terminal peptide of human lactoferrin, further referred to as hLF1-11, was evaluated against K. pneumoniae strains harboring different carbapenemase genes (i.e. OXA-48, KPC-2, KPC-3, VIM-1), with different susceptibility to colistin and other antibiotics, alone or in combination with conventional antibiotics (gentamicin, tigecycline, rifampicin, clindamycin, and clarithromycin)...
October 2017: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/28396547/resistance-to-ceftazidime-avibactam-in-klebsiella-pneumoniae-due-to-porin-mutations-and-the-increased-expression-of-kpc-3
#16
LETTER
Romney M Humphries, Peera Hemarajata
No abstract text is available yet for this article.
June 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28389354/treating-complicated-carbapenem-resistant-enterobacteriaceae-infections-with-ceftazidime-avibactam-a-retrospective-study-with-molecular-strain-characterisation
#17
Fiorella Krapp, Jennifer L Grant, Sarah H Sutton, Egon A Ozer, Viktorija O Barr
Ceftazidime/avibactam (CAZ/AVI) is the first antimicrobial agent with activity against carbapenem-resistant Enterobacteriaceae (CRE) approved by the US Food and Drug Administration (FDA). Notably, human clinical outcome data for this indication are limited. Therefore, a retrospective study was performed to evaluate the clinical outcomes and bacterial genomic characteristics of patients hospitalised at a tertiary medical centre with CRE infections treated for the first time with CAZ/AVI. From a total of 44 patients with CRE infections, 6 patients were treated with CAZ/AVI...
June 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28333331/multiregional-dissemination-of-kpc-producing-klebsiella-pneumoniae-st258-st512-genotypes-in-poland-2010-14
#18
Anna Baraniak, Radoslaw Izdebski, Dorota Zabicka, Katarzyna Bojarska, Sandra Górska, Elzbieta Literacka, Janusz Fiett, Waleria Hryniewicz, Marek Gniadkowski
Objectives: In 2008-09, the KPC carbapenemase epidemiology in Poland was dominated by a Klebsiella pneumoniae ST258 KPC-2 outbreak in Warsaw and its administrative region. The aim of this study was to analyse the situation in 2010-14, with a focus on new outbreaks in other parts of the country. Methods: KPCs were detected in all suspected isolates by PCR. The detailed study was performed on 173 isolates from 2010 to 2012, and included PFGE and MLST, PCR identification of K...
June 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28295617/carbapenemases-producing-klebsiella-pneumoniae-in-hospitals-of-two-regions-of-southern-italy
#19
Carla Calia, Carlo Pazzani, Marta Oliva, Maria Scrascia, Piero Lovreglio, Carmen Capolongo, Anna Maria Dionisi, Adriana Chiarelli, Rosa Monno
Carbapenem-resistant Klebsiella pneumoniae infections are reported with increasing frequency elsewhere in the world, representing a worrying phenomenon for global health. In Italy, there are hotspot data on the diffusion and type of carbapenemase-producing Enterobacteriaceae and K. pneumoniae in particular, with very few data coming from Apulia and Basilicata, two regions of Southern Italy. This study was aimed at characterizing by phenotypic and genotypic methods carbapenem-resistant K. pneumoniae isolated from several Hospitals of Apulia and Basilicata, Southern Italy...
May 2017: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
https://www.readbyqxmd.com/read/28242667/in-vitro-selection-of-meropenem-resistance-among-ceftazidime-avibactam-resistant-meropenem-susceptible-klebsiella-pneumoniae-isolates-with-variant-kpc-3-carbapenemases
#20
Ryan K Shields, M Hong Nguyen, Ellen G Press, Liang Chen, Barry N Kreiswirth, Cornelius J Clancy
Ceftazidime-avibactam resistance is mediated by blaKPC-3 mutations, which restore carbapenem susceptibility. We subjected Klebsiella pneumoniae isolates with different blaKPC-3 mutations (n = 5) or wild-type blaKPC-3 (n = 2) to serial passages with meropenem. The meropenem MIC against each isolate increased. Mutations in the ompK36 porin gene evolved in 5 isolates. Among isolates with D179Y substitutions in KPC-3, blaKPC-3 mutations reverted to wild type, were replaced by new mutations, or were retained. Carbapenem treatment of ceftazidime-avibactam-resistant K...
May 2017: Antimicrobial Agents and Chemotherapy
keyword
keyword
22531
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"